Molecular typing is predicated on molecular genetic testing and isn't but routinely accessible. Molecular subtypes and immunohistochemical surrogate markers of the tumors (HR, HER2, triple damaging) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 can be valuable, but a future